Bile Acids and Their Receptors

Häftad, Engelska, 2020

Del 256 i serien Handbook of Experimental Pharmacology

1 202 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt över 249 kr.

Beskrivning

This book focusses on the latest results related to the field of bile acids as signaling molecules and describes how these receptors have become a major pharmacological target.

Produktinformation

Utgivningsdatum:2020-09-19
Mått:155 x 235 x 21 mm
Vikt:587 g
Format:Häftad
Språk:Engelska
Serie:Handbook of Experimental Pharmacology
Antal sidor:378
Förlag:Springer Nature Switzerland AG
ISBN:9783030220075

Utforska kategorier

Innehållsförteckning

Preface.- Part 1. Bile acids as signaling molecules and their receptors.- 1. A short history of bile acid pharmacology.- 2. Bile acids activated receptors: a review of GPBAR1 (TGR5) and other G-protein-coupled receptors.- 3. Bile acid activated receptors: a review of FXR and other Nuclear receptors.- 4. The intestinal enterokine fibroblast growth factor 15/19 in bile acid metabolism.- 5. Signaling from intestine to the host. How bile acids regulate intestinal and liver immunity.- Part 2. General pharmacology of bile acid activated receptors and their ligands.- 6. Modeling of bile acid activated receptors as a tool for pharmacological development.- 7. Chemistry and pharmacology of GPBAR1 and FXR selective agonists, dual agonists and antagonists.- 8. Non steroidal FXR ligands: current status and clinical applications.- 9. Intestinal selective FXR agonists and their potential in treating liver and metabolic diseases.- Part 3. Bile acids and their derivatives as drugs.- 10. UDCA, Nor-UDCA and T-UDCA: a review of their mechanisms of action and clinical applications.- 11. Chenodeoxycholic acid: an update on its therapeutic appplications and safety profile.- 12. Obeticholic acid: a review of its mechanisms of action and clinical applications.- Part 4. Bile acid activated receptors as therapeutic targets.- 13. Targeting FXR in cholestasis.- 14. FXR agonists for the treatment of NASH and other metabolic disorders.- 15. Targeting bile acids activated receptors in bariatric surgery.